Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.

Samuel DeKoven,Mark Naccarato,Chanson J Brumme,Darrell H S Tan

HIV medicine（2023）

引用 0|浏览4

暂无评分

摘要

Despite a generally high genetic barrier to resistance, NRTI resistance-associated mutations may emerge during therapy with BIC/TAF/FTC in the setting of suboptimal adherence.

查看译文

关键词

antiretroviral therapy, bictegravir, emtricitabine, HIV-1 drug resistance, tenofovir alafenamide

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要